What is the difference between IGF-1 and IGF-1 LR3?

IGF-1 is the endogenous insulin-like growth factor 1 produced mainly by the liver in response to growth hormone. IGF-1 LR3 is a synthetic analog with an extended N-terminal sequence and a single amino acid substitution at position 3. These modifications substantially reduce the molecule's affinity for the insulin-like growth factor binding proteins, which means a higher proportion of the injected dose circulates as the free, receptor-available form rather than being sequestered in binding protein complexes. This extends effective biological activity compared to native IGF-1.

Is IGF-1 LR3 FDA approved?

No. IGF-1 LR3 has not received approval from the FDA, EMA, or any other major regulatory agency for any indication. The only approved recombinant IGF-1 product is mecasermin, which is used under physician supervision in children with severe primary IGF-1 deficiency due to growth hormone insensitivity. IGF-1 LR3 sold as a research chemical is not manufactured under pharmaceutical standards and has no clinical safety or efficacy record from human trials.

How does IGF-1 relate to growth hormone?

Growth hormone does most of its work by stimulating the liver to produce and secrete IGF-1 into the bloodstream. IGF-1 then acts on receptors in muscle, bone, fat, and other tissues to drive the anabolic and metabolic effects associated with GH. Children with growth hormone receptor defects who cannot generate IGF-1 in response to GH show the same growth failure as those with GH deficiency itself. The two hormones work as a linked axis rather than independently.

What did the ALS clinical trials show for IGF-1?

A phase 3 trial published in 1997 in Nature Medicine found modest slowing of ALS functional decline with IGF-1 treatment, but the effect size was not large enough to support regulatory approval. A subsequent multicenter European trial produced inconsistent results. IGF-1 is not a standard or approved treatment for ALS as a result, though it remains a compound of research interest for neuroprotection given IGF-1 receptor expression in motor neurons.

What are the main safety concerns with IGF-1?

Hypoglycemia is the most documented acute risk because IGF-1 activates the insulin receptor as well as its own receptor. Mecasermin, the approved pharmaceutical form, lists hypoglycemia as a common adverse effect and requires carbohydrate intake around dosing. Intracranial hypertension and tonsillar or adenoid hypertrophy have also been observed with therapeutic IGF-1 use in children. Epidemiological data associating higher normal-range IGF-1 levels with modest increases in prostate, colorectal, and breast cancer risk adds a longer-term concern for supraphysiologic or long-term exposure scenarios.

Is IGF-1 LR3 detectable in drug testing?

IGF-1 and its analogs are on the WADA prohibited list as peptide hormones and related substances. Detection approaches have historically focused on indirect biomarker methods rather than direct compound detection, given the short detection windows. As anti-doping methods have improved, direct detection of analogs has become more feasible. Any athlete in a WADA-regulated sport should treat IGF-1 LR3 as a substance that carries real detection and sanction risk.

IGF-1 LR3: The Insulin-Like Growth Factor Research Guide

Published: April 30, 2026•Updated: April 30, 2026

Research use only. This article discusses compounds that include approved medications, investigational drugs, and research peptides. Material sold for research is not cleared for human administration and is not a substitute for medical advice.

Insulin-like growth factor 1 sits at the center of one of the most studied signaling axes in endocrinology. Growth hormone alone does not directly build muscle or regulate cellular metabolism. It does most of its work by telling the liver to produce IGF-1, which then circulates to tissues throughout the body. This article covers how that axis works, why researchers developed a modified version called IGF-1 LR3, what the clinical trial record looks like, and what the regulatory landscape means for anyone encountering this compound in a research context.

IGF-1 and the growth hormone axis

Insulin-like growth factor 1 is a 70 amino acid peptide hormone produced primarily in the liver. Its production is driven by growth hormone, which is released in pulses from the pituitary gland throughout the day, with the largest pulses occurring during deep sleep. When growth hormone reaches hepatocytes in the liver, it triggers IGF-1 synthesis and secretion into the bloodstream.

The name reflects a structural resemblance to proinsulin. Both molecules activate receptor tyrosine kinases, and IGF-1 can bind weakly to the insulin receptor, which is one reason elevated IGF-1 signaling is associated with changes in glucose metabolism. The IGF-1 receptor itself is distinct, and its downstream signaling through the PI3K/Akt and MAPK/ERK pathways promotes protein synthesis, cell proliferation, and inhibits programmed cell death.

GH does not act alone

Growth hormone has both direct effects on tissues and indirect effects mediated through IGF-1. The indirect effects are substantial. Children with Laron syndrome, who have growth hormone receptor defects and therefore cannot produce IGF-1 in response to GH, show the same growth failure as children who produce no growth hormone at all. The IGF-1 step in the axis is not optional.

In adults, IGF-1 continues to regulate lean body mass, bone density, and cellular repair processes, though levels decline progressively with age beginning in the third decade of life. By age 60, circulating IGF-1 levels are roughly half what they were at age 20 in most individuals. Whether this decline is pathological or a normal protective response to aging remains an active area of debate in the research literature.

Why circulating IGF-1 is complicated to measure

Almost all circulating IGF-1 travels bound to one of six insulin-like growth factor binding proteins, called IGFBPs. IGFBP-3 carries the largest share, roughly 75 to 80 percent of total IGF-1 in a ternary complex that also includes a large protein called the acid-labile subunit. This complex is too large to cross capillary membranes, which means the bound form is essentially a circulating reservoir rather than an immediately active fraction.

Free IGF-1, the fraction available to bind receptors in tissues, represents only about one to two percent of total circulating IGF-1 and has a very short half-life when not bound. The binding proteins regulate how much free IGF-1 is available at any given time and in any given tissue, which is one reason the relationship between serum IGF-1 levels measured in a blood test and actual cellular IGF-1 activity in tissues is not straightforward.

Total serum IGF-1

The standard clinical measurement. Reflects the sum of bound and free fractions. Used to diagnose growth hormone deficiency and acromegaly, and to monitor IGF-1 replacement therapy. Does not directly indicate how much IGF-1 is actively signaling at the tissue level.

Free IGF-1

A smaller fraction not bound to IGFBPs. More directly reflects receptor-available hormone. Assays exist but are technically challenging and less commonly ordered in standard clinical practice.

IGF-1 in tissue

Local IGF-1 production also occurs in muscle, bone, and other tissues in response to mechanical loading and injury, independent of liver-derived circulating IGF-1. This paracrine and autocrine IGF-1 is not captured by serum measurements at all.

What the LR3 modification does

Native recombinant IGF-1 administered by injection faces two practical problems in research settings. First, it binds tightly to the IGFBPs in circulation, which reduces the free fraction available to reach tissue receptors. Second, when free IGF-1 is not complexed with binding proteins, it clears rapidly. Researchers engineered the LR3 variant to address both issues.

The modification involves two changes to the native sequence. The first is the addition of a 13 amino acid extension at the N-terminus of the peptide. The second is a single amino acid substitution at position 3, replacing arginine with glutamic acid. Together, these changes reduce IGF-1's affinity for the binding proteins by roughly 1,000-fold in preclinical binding studies. The LR3 designation simply describes these features: Long refers to the N-terminal extension, R3 refers to the amino acid 3 substitution.

Longer circulation, higher tissue activity

By avoiding the binding proteins, IGF-1 LR3 spends more time as the free, receptor-available form rather than sequestered in the IGFBP-3 reservoir. Preclinical pharmacokinetic studies report substantially longer effective half-lives compared to native IGF-1, though the exact values vary by species and study design. This property made it useful in research contexts where sustained IGF-1 receptor stimulation was needed.

The same IGFBP avoidance property that extends circulation also changes the tissue distribution pattern. Native IGF-1 in the IGFBP-3 ternary complex is largely confined to the vascular compartment until the complex disassembles. IGF-1 LR3, having lower binding protein affinity, distributes more freely to tissues. In animal models this translated to greater anabolic effects on skeletal muscle at equivalent doses compared to native IGF-1.

Clinical research and approved uses

The pharmaceutical development of IGF-1 as a therapeutic followed two paths. The first was native recombinant IGF-1, called mecasermin, which received FDA approval in 2005 under the brand name Increlex for a specific pediatric indication: severe primary IGF-1 deficiency due to growth hormone insensitivity, most prominently Laron syndrome. This is a rare genetic condition in which the growth hormone receptor functions poorly or not at all, leaving patients with normal or elevated GH but very low IGF-1.

The second pharmaceutical path involved a combination product pairing recombinant IGF-1 with recombinant IGFBP-3, called mecasermin rinfabate, which was approved briefly but later withdrawn from the US market by its manufacturer in 2008 for commercial reasons rather than safety concerns.

IGF-1 has been investigated in a broader set of conditions including amyotrophic lateral sclerosis, HIV-associated wasting, and type 1 diabetes, with the rationale that IGF-1's anabolic and neuroprotective properties might be beneficial. The ALS trials are the most notable. A phase 3 trial published in 1997 in Nature Medicine showed modest slowing of functional decline that did not reach the threshold for regulatory approval. A subsequent European multicenter trial produced conflicting results, and IGF-1 has not become a standard treatment for ALS.

•Mecasermin (native recombinant IGF-1) is FDA-approved for severe primary IGF-1 deficiency in children.
•Clinical trials in ALS showed inconsistent results and did not support regulatory approval for that indication.
•IGF-1 LR3 specifically has not received regulatory approval for any indication from the FDA or EMA.
•Research use of IGF-1 LR3 is in preclinical and cell culture settings, where its longer half-life is an advantage for experimental design.
•Elevated IGF-1 in observational studies has been associated with increased risk of certain cancers, which has influenced the risk-benefit calculus in therapeutic development.

IGF-1 and body composition research

Skeletal muscle expresses IGF-1 receptors at high density, and IGF-1 signaling through the Akt/mTOR pathway is one of the primary anabolic pathways in muscle. This biology has driven substantial interest in IGF-1 as a potential therapeutic for muscle wasting conditions, sarcopenia associated with aging, and cachexia in chronic disease.

Animal studies using IGF-1 LR3 have consistently shown increased lean mass, enhanced muscle protein synthesis, and accelerated recovery from hindlimb immobilization in rodent models. These results established the compound's utility as a research tool for studying IGF-1 receptor signaling and anabolic pathways in skeletal muscle. Translating animal data to human outcomes has proven difficult across the broader field of anabolic peptide research.

The growth hormone and IGF-1 axis also interacts substantially with the insulin signaling system. IGF-1 can lower blood glucose through insulin receptor cross-activation, and the relationship between GH, IGF-1, insulin resistance, and body fat distribution is a recurring theme in metabolic research. Men with growth hormone deficiency develop increased visceral adiposity and insulin resistance, and IGF-1 replacement in that specific deficient population improves metabolic markers. Whether supraphysiologic IGF-1 stimulation in otherwise healthy adults produces the same benefits or creates different risks is not established.

The cancer question

Epidemiological studies have found associations between higher IGF-1 levels within the normal physiologic range and modestly increased risks of prostate, colorectal, and premenopausal breast cancer. This association does not establish causation, and the absolute risk differences in these studies are small. It does, however, mean that the risk-benefit calculation for IGF-1 therapies in non-deficient populations requires careful consideration, particularly over longer treatment durations.

Regulatory status and research context

IGF-1 LR3 is not approved by the FDA, EMA, or any comparable regulatory body for human therapeutic use. It is classified as a research chemical when sold for laboratory purposes, meaning it has no prescribing information, no manufacturing standards equivalent to pharmaceutical-grade production, and no clinical safety database from controlled human trials.

The approved IGF-1 product, mecasermin, is itself a controlled and monitored medication used only in a specific pediatric population under physician supervision, with known adverse effects including hypoglycemia, intracranial hypertension, and tonsillar hypertrophy at therapeutic doses. The safety profile of IGF-1 LR3 in humans has not been characterized in published clinical trials.

In competitive sports, IGF-1 and its analogs are prohibited under the World Anti-Doping Agency list as peptide hormones and growth factors. Detection has historically been challenging due to the short window of altered biomarkers, but detection methods have continued to improve. Athletes in any WADA-regulated sport face career consequences if found positive regardless of the source of the compound.

•IGF-1 LR3 has no FDA or EMA approval for any indication.
•The only approved IGF-1 product is mecasermin, used in children with severe primary IGF-1 deficiency.
•Research chemicals labeled as IGF-1 LR3 are sold for laboratory use and are not subject to pharmaceutical manufacturing standards.
•IGF-1 and analogs are prohibited in WADA-regulated sports.
•Hypoglycemia is the most documented acute risk of IGF-1 administration, given the hormone's insulin-like actions at the insulin receptor.